We are pleased to announce the launch of three new HIV-1 antigen products—8H12, 8H13, and 8H16—that expand our portfolio of solutions for HIV diagnostics. This launch also reinforces Hytest’s commitment to public health. We remain dedicated to supporting global efforts in the fight against HIV/AIDS. Early and accurate diagnosis is critical for timely treatment and improved patient outcomes, and our products are poised to make a meaningful impact in this area.

All three antigens were developed with rigorous validation and manufactured under strict quality controls. These recombinant proteins deliver the sensitivity, specificity, and consistency required by diagnostic developers across a range of assay platforms.

During HIV-1 infection, antibody responses develop at different times. Antibodies to gp41 are among the earliest to appear, often detectable within 2–3 weeks post-infection, which makes gp41 a valuable target for early diagnostic assays. By contrast, antibodies to the gp120 V3 loop generally arise later, although the V3 region is highly immunogenic once exposed. To provide broad and reliable diagnostic coverage, Hytest antigens include conserved, immunodominant regions such as HIV-1 gp41 and the gp120 V3 loop. These targets were selected for their early seroconversion profiles, high immunogenicity, and ability to represent the genetic diversity of HIV-1 (groups M and O, multiple subtypes, and CRFs). In addition, the Hytest HIV-1 antigen shows low sequence identity to HIV-2, which reduces cross-reactivity and supports HIV-1–specific detection. For comprehensive detection of both HIV-1 and HIV-2, these antigens can be used alongside an HIV-2 antigen (coming soon!).

In the meantime, don’t miss our anti-HIV p24 antibodies (Cat. # 3H24), optimized for fourth- and fifth-generation HIV assay development. For detailed product information, technical support, or sample requests, please reach out to our Sales team.

Data Sheet

Cat. # 8H12

Cat. #8H13

Cat. # 8H16

Cat. # 3H24